Overview

Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-06-17

Target enrollment:

Participant gender:

Summary

This is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa. Participants will be randomized 2:1 to either sonelokimab or matching placebo up to Week 16.

Phase:

PHASE3

Details

Lead Sponsor:

MoonLake Immunotherapeutics AG

Treatments:

sonelokimab